News & Events about C4 Therapeutics Inc.
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today ...
Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone Phase 1/2 Trial of CFT8634, a BRD9 BiDAC Degrader, Continues to Progress with Phase 1 ...
Ticker Report
2 months ago
Vickers Vantage Corp. I (NASDAQ:VCKA Get Rating) and C4 Therapeutics (NASDAQ:CCCC Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability...
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 3,900,000 shares, a decline of 23.7% from the April 30th total of 5,110,000 shares. Currently, 10.2% of the companys shares are short sold. ...
Globe Newswire
9 months ago
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C4 Therapeutics, Inc. (C4 or the Company) (NASDAQ: CCCC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation ...